Market capitalization | AUD646.28m |
Enterprise Value | AUD463.29m |
P/E (TTM) P/E ratio | 18.15 |
EV/FCF (TTM) EV/FCF | 14.72 |
EV/Sales (TTM) EV/Sales | 5.25 |
P/S ratio (TTM) P/S ratio | 7.33 |
P/B ratio (TTM) P/B ratio | 3.18 |
Dividend yield | 0.39% |
Last dividend (FY24) | AUD0.05 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Clinuvel Pharmaceutical forecast:
7 Analysts have issued a Clinuvel Pharmaceutical forecast:
Jun '24 |
+/-
%
|
||
Revenue | 88 88 |
13%
13%
|
|
Gross Profit | 58 58 |
6%
6%
|
|
EBITDA | 45 45 |
7%
7%
|
EBIT (Operating Income) EBIT | 44 44 |
6%
6%
|
Net Profit | 36 36 |
16%
16%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Philippe Wolgen |
Founded | 1999 |
Website | www.clinuvel.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.